Eric Hobbs - 11 May 2022 Form 4 Insider Report for Berkeley Lights, Inc. (BLI)

Role
President - Antibody Therapeutics
Signature
/s/ Christine Nassi, Attorney-in-fact for Eric Hobbs
Issuer symbol
BLI
Transactions as of
11 May 2022
Transactions value $
-$952,003
Form type
4
Filing time
13 May 2022, 19:53:18 UTC
Previous filing
22 Mar 2022
Next filing
23 May 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLI Common Stock Options Exercise $833 +1.3K +0.35% $0.64* 374K 11 May 2022 Direct
transaction BLI Common Stock Options Exercise $24K +37.5K +10.03% $0.64* 411K 11 May 2022 Direct
transaction BLI Common Stock Sale -$410K -98K -23.83% $4.18* 313K 11 May 2022 Direct F1, F2
transaction BLI Common Stock Sale -$530K -123K -39.28% $4.31* 190K 12 May 2022 Direct F1, F3
transaction BLI Common Stock Sale -$37.4K -7.53K -3.96% $4.97* 183K 13 May 2022 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLI Stock Option (Right to Buy) Options Exercise $0 -1.3K -100% $0.00* 0 11 May 2022 Common Stock 1.3K $0.64 Direct F4
transaction BLI Stock Option (Right to Buy) Options Exercise $0 -37.5K -100% $0.00* 0 11 May 2022 Common Stock 37.5K $0.64 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan.
F2 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.66. The reporting person undertakes to provide Berkeley Lights, Inc. (the "Company"), any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F3 The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $3.97 to $4.50. The reporting person undertakes to provide the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4 The stock option is currently exercisable.

Remarks:

President - Antibody Therapeutics